CBS Top News｜前美国食品药品监督管理局（FDA）局长警告称，由于缺乏长期使用的数据，减肥药物没有“最终结局”Weight loss drugs have transformed how Americans lose weight, including former commissioner for the U.S. Food and Drug Administration
目前批准用于治疗肥胖或超重患者的 GLP-1 RA 的处方信息包含有关自杀意念和行为风险的信息。根据这些药物的处方信息,医生应监测使用 GLP-1 RA 的患者,并建议患者报告。 后续评估中,FDA 将对所有 GLP-1 RA 产品的临床试验进行大型、综合的荟萃分析,并对药物上市后数据进行分析。 FDA 同时表示,将在完成审查或有更...
Other GLP-1 prescription drugs, like Ozempic (a subcutaneous injection) or Rybelsus (oral tablets), also contain semaglutide and can lead to weight loss, but are approved to treat type 2 diabetes, together with diet and exercise (not weight loss) at this time....
12月1日,EMA风险评估委员会(PRAC)表示,已评估了所有来自临床试验、上市后监测和已发表文献的所有可用证据,里面包含了GLP-1RA引发自杀/自残意念的报告病例,但目前暂不能作出自杀意念和GLP-1之间具有因果关系的结论,需要进一步了解相关潜在风险,要求GLP-1药物生产商对相关药物多个方面的问题作出澄清。 2024年1月5日,Na...
Weight loss is a common New Year's resolution and studies show more people are turning to weight loss drugs, like Ozempic and Wegovy. Both are GLP-1 drugs, which stands for glucagon-like peptide-1, a natural hormone that helps regulate blood sugar, slow down digestion and reduce appetite....
2. What do I do if I'm currently taking a compounded version of a weight loss medication? ABC News chief medical correspondent Dr. Tara Narula said Tuesday on "Good Morning America" that the FDA's decision to halt the making of compound versions of GLP-1 drugs will impact many pe...
10 月 5 日,JAMA 在线发布题为 Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss 的研究,探讨了使用 GLP-1 类激动剂与胃肠道不良反应的相关性。 图源:JAMA 研究发现,与使用安非他酮-纳曲酮(FDA 批准的一种具有不同作用机制的减肥药物)相比,...
反观反观诺德诺的的GLP-1资产,如果将semaglutide为活性物质的药物Ozempic,Wegovy和Rybelsus“合并同类项”,它们在2024年的销售总额估计能够超过280亿美元,从而超越Keytruda成为全球药王(图1)。 普遍认为2030年GLP-1多肽减肥药将拥有800-1000亿美元的市场。 图1 预计2024年全球...
Common side effects of GLP-1 medications can include stomach-related issues such as nausea, vomiting, diarrhea, constipation, and stomach pain. Some people may experience a decreased appetite, which can lead to weight loss. These medications can also lower blood sugar levels, potentially causing lo...
The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound. The medicine, part of the class known as GLP-1 receptor agonists that also includes Ozempic, was cleared to treat moderate to severe forms of the ...